CD19 and multiple sclerosis: Tα1 treatment enhanced expansion of CD19+CD24+CD38hi transitional-immature and CD24low/negCD38hi plasmablast-like regulatory B cell subsets, thus inducing anti-inflammatory status and improving multiple sclerosis.